Jiangsu Kanion Pharmaceutical Co. Ltd. Class ASSE: 600557

Announcement on the Receipt of the Clinical Trial Approval Notice for Jinzhen Oral Liquid with Increased Indications

· Issued by Jiangsu Kanion Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on the Receipt of the Clinical Trial Approval Notice for Jinzhen Oral Liquid with Increased Indications

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment